A detailed history of Vanguard Group Inc transactions in Repare Therapeutics Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 55,097 shares of RPTX stock, worth $72,728. This represents 0.0% of its overall portfolio holdings.

Number of Shares
55,097
Previous 55,545 0.81%
Holding current value
$72,728
Previous $183,000 3.28%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$2.75 - $3.99 $1,232 - $1,787
-448 Reduced 0.81%
55,097 $189,000
Q2 2024

Aug 13, 2024

SELL
$3.02 - $4.7 $893 - $1,391
-296 Reduced 0.53%
55,545 $183,000
Q1 2024

May 10, 2024

SELL
$4.53 - $8.41 $30,885 - $57,339
-6,818 Reduced 10.88%
55,841 $263,000
Q4 2023

Feb 14, 2024

SELL
$3.22 - $11.79 $39,937 - $146,231
-12,403 Reduced 16.52%
62,659 $457,000
Q3 2023

Nov 14, 2023

BUY
$8.16 - $13.01 $4,080 - $6,505
500 Added 0.67%
75,062 $906,000
Q2 2023

Aug 14, 2023

SELL
$8.63 - $12.53 $4,660 - $6,766
-540 Reduced 0.72%
74,562 $788,000
Q4 2022

Feb 10, 2023

BUY
$12.5 - $18.13 $15,750 - $22,843
1,260 Added 1.71%
75,102 $1.1 Million
Q3 2022

Nov 14, 2022

BUY
$11.57 - $15.59 $6,942 - $9,354
600 Added 0.82%
73,842 $895,000
Q2 2022

Aug 12, 2022

BUY
$8.45 - $14.84 $74,131 - $130,191
8,773 Added 13.61%
73,242 $1.02 Million
Q1 2022

May 13, 2022

BUY
$11.38 - $21.88 $4,096 - $7,876
360 Added 0.56%
64,469 $918,000
Q4 2021

Feb 14, 2022

BUY
$19.66 - $28.11 $571,417 - $817,017
29,065 Added 82.94%
64,109 $1.35 Million
Q3 2021

Nov 12, 2021

BUY
$25.71 - $35.24 $32,651 - $44,754
1,270 Added 3.76%
35,044 $920,000
Q2 2021

Aug 13, 2021

BUY
$30.1 - $34.85 $1.02 Million - $1.18 Million
33,774 New
33,774 $1.05 Million

Others Institutions Holding RPTX

About Repare Therapeutics Inc.


  • Ticker RPTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 41,937,800
  • Market Cap $55.4M
  • Description
  • Repare Therapeutics Inc., a clinical-stage precision oncology company, discovers and develops therapeutics by using its synthetic lethality approach in Canada and the United States. The company uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform to systematically discover and develop highly targeted cancer therapies that foc...
More about RPTX
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.